Table 3.
Patients with at least 1 visit to a primary care provider participating in the Canadian Primary Care Sentinel Surveillance Network between January 1, 2017 and December 31, 2019 (N = 689,301)
| Variable name | Patients without CVD n = 612,237 | Patients with CVD (Case Definition 2) n = 77,064 | P |
|---|---|---|---|
| Patient sex, male | 258,657 (42.3) | 42,644 (55.4) | < 0.0001 |
| Patient age, mean (SD) | 50.0 (18.7) | 70.5 (14.4) | < 0.0001 |
| Annual visit frequency, mean (SD) | 2.6 (3.0) | 4.8 (5.5) | < 0.0001 |
| Systolic BP, mm Hg, mean (SD) | 125 (16) | 130 (17) | < 0.0001 |
| Diastolic BP, mm Hg, mean (SD) | 76.8 (10) | 74 (11) | < 0.0001 |
| Obesity (BMI ≥ 30) | 35,965 (5.9) | 6483 (8.4) | < 0.0001 |
| Diabetes | 68,515 (11.2) | 23,169 (30.1) | < 0.0001 |
| Hypertension | 148,654 (24.3) | 47,509 (61.7) | < 0.0001 |
| Heart failure | 14,003 (2.3) | 15,187 (19.7) | < 0.0001 |
| Dyslipidemia | 211,529 (34.6) | 55,992 (72.7) | < 0.0001 |
| CVD medication | 151,236 (24.7) | 57,924 (75.2) | < 0.0001 |
| Cardiac therapy | 7935 (1.3) | 18,917 (24.6) | < 0.0001 |
| Beta-blockers | 44,886 (7.3) | 33,555 (43.5) | < 0.0001 |
| Calcium-channel blockers | 59,365 (9.7) | 25,720 (33.4) | < 0.0001 |
| ACE inhibitors | 81,693 (13.3) | 37,563 (48.7) | < 0.0001 |
| ARB | 47,782 (7.8) | 17,544 (22.8) | < 0.0001 |
Values are n (%), unless otherwise indicated.
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; SD, standard deviation.